Synopsis: Anupam Rasayan has entered the next phase of its ₹1,370 crore acquisition of Bliss GVS Pharma by dispatching the Letter of Offer for its mandatory open offer. If the offer receives full acceptance, the company could secure nearly 70% ownership while retaining Bliss GVS Pharma as a listed entity, marking a significant milestone in its inorganic growth strategy.
The pharmaceutical industry continues to witness strategic consolidation as companies pursue acquisitions to expand product portfolios, strengthen manufacturing capabilities, and establish a larger presence across domestic and international markets. Such transactions often trigger mandatory open offers under SEBI’s takeover regulations, allowing public shareholders an opportunity to participate in a change of control.
Shares of Anupam Rasayan Limited were trading at Rs 1,255.1, down by 0.89 percent from the previous close of Rs 1,266.4. The stock opened at an intraday high of Rs 1,272, and the day’s low is Rs 1,253.3. The company currently has a market capitalisation of Rs 14,322 crore.
Anupam Rasayan Launches ₹829 Crore Open Offer
Anupam Rasayan India Ltd. shares may remain in focus following its mandatory open offer to acquire up to 2,77,26,848 equity shares (26% of Bliss GVS Pharma Ltd.’s expanded voting share capital) at a price of ₹299 per share. The open offer has a maximum cash consideration of ₹829.03 crore, assuming full acceptance. An open offer allows public shareholders to sell their shares to the acquirer when a company acquires a significant stake or control in a listed company under SEBI’s takeover regulations.
The open offer forms part of Anupam Rasayan’s previously announced ₹1,369.51 crore acquisition of 4,58,03,024 equity shares, representing 43.11% of Bliss GVS Pharma’s equity share capital, through a Share Purchase Agreement (SPA).
A Share Purchase Agreement is a legally binding agreement that outlines the terms, price, and conditions of the share acquisition. The transaction, structured as an all-cash deal at ₹299 per share, triggered the mandatory open offer under Regulations 3(1) and 4 of the SEBI (SAST) Regulations due to the acquisition of both substantial shareholding and management control.
The Letter of Offer also notes that the originally announced 43.30% acquisition stake has now been revised to 43.11% after Bliss GVS Pharma allotted additional equity shares pursuant to the exercise of employee stock options, increasing the company’s outstanding equity capital.
SPA Includes Additional Call Option for Higher Ownership
Apart from the acquisition of the controlling stake, the Share Purchase Agreement grants Anupam Rasayan a call option-the right, but not the obligation, to purchase additional shares in the future under pre-agreed terms-to acquire up to 51,81,571 equity shares, representing around 4.88% of Bliss GVS Pharma’s current equity share capital.
These Option Shares can be acquired on the Closing Date at ₹299 per share. If the company does not exercise the option in full at closing, it retains the right to acquire the remaining shares between six and twelve months after the closing date, on the first anniversary of the closing date, or on any mutually agreed date.
The deferred acquisition will occur at the prevailing market price; however, if the market price falls below ₹299 per share, the shares can still be acquired off-market at ₹299 per share, providing downside price protection.
Ownership Could Increase to 69.21%
Assuming the open offer is fully subscribed, Anupam Rasayan’s total holding in Bliss GVS Pharma would increase to approximately 69.21% of the company’s equity share capital. This is marginally lower than the earlier projected 69.51%, reflecting the increase in Bliss GVS Pharma’s outstanding shares following ESOP allotments.
The company also stated that it will not delist Bliss GVS Pharma after the acquisition. The Letter of Offer also states that the open offer is not conditional on a minimum level of acceptance, ensuring that SEBI’s takeover regulations will be followed regardless of the number of shares tendered.
Offer Timeline and PAC Structure
The Letter of Offer was dispatched to eligible public shareholders on 21 July 2026, while the tendering period will open on 28 July 2026 and close on 10 August 2026. Shareholders whose shares are accepted under the offer are expected to receive consideration by 24 August 2026, followed by the post-offer public announcement and filing of the final report with SEBI by 1 September 2026.
The filing also states that Mates Visa Consultancy Private Limited, now a wholly owned subsidiary of Anupam Rasayan, has been designated as the Person Acting in Concert (PAC) after executing a Deed of Adherence on 17 July 2026. The PAC will acquire the shares tendered in the open offer and will be bound by the terms of the Share Purchase Agreement alongside the acquirer.
Strategic Insight and Industry Analysis
The acquisition structure reflects a phased ownership strategy rather than a one-time purchase. Along with the acquisition of a 43.11% controlling stake and the mandatory 26% open offer, the Share Purchase Agreement provides Anupam Rasayan with a call option to acquire an additional 4.88% stake, allowing the company to consolidate ownership over time while retaining flexibility on execution. The built-in minimum acquisition price of ₹299 per share for deferred purchases also offers protection against adverse market movements.
The filing also states that the company wants long-term management control, not privatisation. Anupam Rasayan can integrate the pharmaceutical business while maintaining access to public capital markets and meeting SEBI’s minimum public shareholding norms by confirming that Bliss GVS Pharma will remain listed after the acquisition. Investors will likely watch the open offer, call option exercise, and Bliss GVS Pharma’s integration into Anupam Rasayan’s long-term growth strategy.
Anupam Rasayan India Ltd is a specialty chemical manufacturer engaged in custom synthesis and specialty chemicals catering to global customers across life sciences and other end-user industries, including agrochemicals, pharmaceuticals, polymers, personal care, and performance materials.
Bliss GVS Pharma Ltd. is a pharmaceutical company engaged in the development, manufacturing, and marketing of formulations across multiple therapeutic segments, with a presence in both domestic and international markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
